Survey: Hydroxychloroquine use fairly common in COVID-19
April 29, 2020
Testing and preparedness have increased, but a return to normal life could take another 6 months.
FDA reiterates hydroxychloroquine limitations for COVID-19
April 24, 2020
An FDA Safety Communication restates that hydroxychloroquine and chloroquine are only for hospitalized COVID-19 patients who can’t enter a trial.
Angiotensin drugs and COVID-19: More reassuring data
April 24, 2020
Data from one Wuhan hospital show no difference in COVID-19 severity or mortality in patients with hypertension taking ACE inhibitors or ARBs. Other reassuring studies are also emerging.
Hydroxychloroquine ineffective for COVID-19, VA study suggests
April 23, 2020
The retrospective study, which included data from 368 men hospitalized with confirmed COVID-19 and treated in VA medical centers, showed an association between HCQ and higher mortality.
Signature STEMI sign may be less diagnostic in the COVID-19 age
April 22, 2020
ST-segment elevation, often a ticket to the cath lab, may not indicate STEMI as reliably as before hospitals started to fill with COVID-19 patients, who may have other ST-segment–elevating conditions.
COVID-19: U.S. cardiology groups reaffirm continued use of RAAS-active drugs
March 18, 2020
Experts give ACE inhibitors and ARBs, cornerstones of cardiology therapy, a thumbs up despite a hypothetical adverse COVID-19 effect.
COVID-19: Older patients with cancer especially vulnerable
March 12, 2020
Expert advises diligence in screening cancer patients and commonsense preventative measures.